Navigation Links
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Date:6/16/2008

Data from Phase 1 Single Agent and Phase 1b Combination Clinical Trials

Demonstrate Voreloxin's Anti-Leukemic Activity

SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented data Saturday from two clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), including updated results of a Phase 1 trial of voreloxin when used as a single agent in relapsed or refractory patients with acute myeloid leukemia (AML) and preliminary data from a Phase 1b trial of voreloxin in combination with cytarabine in patients with relapsed/refractory AML.

"Voreloxin has demonstrated anti-leukemic activity as a single agent and is showing encouraging early response data when administered in combination with cytarabine. Importantly, it has also been generally well tolerated, even among patients older than 60 and patients with AML with poor risk features," said Judith E. Karp, M.D., Director, Adult Leukemia Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University and an investigator for the Phase 1 and Phase 1b clinical trials of voreloxin in AML. "Voreloxin appears to be a promising new drug for the treatment of AML and I look forward to the results of continued clinical investigation."

Analysis of Safety and Response Data for Older AML Patients Supports Phase 2 REVEAL-1 Trial

Researchers presented an analysis of comparative safety, pharmacokinetic and response data from Sunesis' Phase 1 dose-escalating trial of single-agent voreloxin comparing results from older patients (age >/= 60) with those from younger patients (age < 60). Overall, voreloxin demonstrates a similar safety profile in both older and you
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
2. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
3. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
4. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
5. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
9. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
10. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
11. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 , Industry ... the inaugural Tweetchat taking place in real-time at ... organised by UBM Live , announces the ... a first of its kind global industry-wide Tweetchat ... supply chain, aimed to stimulate conversations on key ...
(Date:8/28/2014)... , Aug. 28, 2014  Rigrodsky & Long, P.A.: ... Company, Inc. (NYSE: LCI )? , Did you ... 2013 and July 16, 2014, inclusive? , Did you ... Do you want to discuss your rights? ... United States Attorney, Timothy J. MacFall , announces that a ...
(Date:8/28/2014)... 2014 Reportlinker.com announces that a new ... Germany Aesthetic Lasers and Energy Devices ... http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html Germany Aesthetic Lasers and ... GlobalData,s new report, "Germany Aesthetic Lasers and ... market data on the Germany Aesthetic Lasers and ...
Breaking Medicine Technology:CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Selling cigarettes ... or illegal tobacco and doesn,t harm sales in small ... problems were predicted by the tobacco industry when it ... in the world to introduce plain packaging for tobacco ... Ireland, New Zealand and the U.K. Researchers surveyed ...
(Date:8/29/2014)... August 29, 2014 Honey Gifts, premium ... company will now be selling purse-sized adult toys and ... way that they can be carried in a woman’s ... the purse-sized range at Honey Gifts is also leak-free ... life and rechargeable batteries are common characteristics of Honey ...
(Date:8/29/2014)... Barbara, CA (PRWEB) August 29, 2014 ... in Santa Barbara in the Santa Barbara News-Press Readers’ ... Evolutions won the Readers’ Choice poll as Best Medical ... 20, 2014 reads the following about Evolutions Medical Spa ... spa, but it is recognized as a top-notch, cutting-edge ...
(Date:8/29/2014)... COLUMBUS, Ohio (PRWEB) August 29, 2014 ... vice president of operations & business development. , Rees ... the vice president of business development. , A wholly ... (OPRS), Senior Independence provides older adults with options, including ... teams, in-home care (e.g., meal preparation) and therapeutic adult ...
(Date:8/29/2014)... Last week, the Fed reported an increase in ... rose to 0.4% while manufacturing output progressed to 1.0%. ... boost since February this year. Capacity use has increased by ... – an increase that could be attributed to the boost ... which is a measure of slack across the industries. , ...
Breaking Medicine News(10 mins):Health News:Study Counters Critics of Plainer Cigarette Packaging 2Health News:Honey Gifts Now Provides Purse Sized Adult Toys in Vancouver 2Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 2Health News:Evolutions Named Best Medical Spa in Santa Barbara by Santa Barbara News Press 3Health News:Senior Independence Promotes Rees to Vice President of Operations & Business Development 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 3
... Findings may explain link between breathing in dirty air ... -- Long-term exposure to the air pollution particles caused ... blood pressure, U.S. researchers say. , In the new ... Normative Aging Study, who were assessed every four years ...
... warmer than 75 degrees poses added risks , THURSDAY, March ... deaths in New York City go up with the temperature: ... 75 degrees Fahrenheit. , The findings, published online March ... death statistics in the city from 1990 through 2006. , ...
... ... ... ... ...
... replicate the human brain, or to develop nanotechnology that ... neurons and other types of cellular networks? Once ... other in ways that could propel extraordinary new research. ... an hour-long conversation recently led by neuroscientist Nicholas Spitzer. ...
... , ... ... ... ...
... Henry Ford Hospital study has shown a link between Vitamin ... lead researchers to better understand the development of the most ... researchers at Henry Ford and Wayne State University found elevated ... taken from 10 patients compared to normal skin tissue taken ...
Cached Medicine News:Health News:Years of Exposure to Traffic Pollution Raises Blood Pressure 2Health News:Anthera Pharmaceuticals Completes Initial Public Offering 2Health News:Anthera Pharmaceuticals Completes Initial Public Offering 3Health News:Anthera Pharmaceuticals Completes Initial Public Offering 4Health News:Anthera Pharmaceuticals Completes Initial Public Offering 5Health News:Anthera Pharmaceuticals Completes Initial Public Offering 6Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 2Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 3Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 4Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 5Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 6Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 7Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 8Health News:Dermatologists Can Help Women Win the Fight Against Common Forms of Hair Loss 9
... scale accommodates standard to extra-wide wheelchairs (18" ... The low-profile, heavy-duty, anodized aluminum weighing platform ... high providing easy access for large patients. ... steel digital readout. The 6772 has the ...
This high-capacity stand-on scale provides extra sensitivity and support to patients who are unsteady on their feet. Advanced technology compensates for patient movement....
... 100 provides a new screening, diagnostic, treatment ... medical management of sleep-related breathing disorders. The ... unmet need for an ambulatory, reliable, patient ... to the great number of OSA sufferers, ...
... synthesized by the parathyroid glands [1,2] ... extracellular calcium concentrations. PTH prevents hypocalcemia ... calcium excretion by the kidney. Following ... is rapidly degraded into 4 fragments: ...
Medicine Products: